Live Last read · last published · next check
For the first time, INCATE’s Selection Committee didn’t simply meet — they came together in person at the headquarters of one of our industry partners, creating an atmosphere in Munich filled with energy, curiosity, and a shared commitment to innovation. What began as a session to evaluate new ventures quickly evolved into something much bigger: [...] The post From discussion to discovery: meet…
Obulytix has had an exciting start to the year, marked by important milestones and strengthening the contribution to the fight against antimicrobial resistance. Obulytix joined the END2AMR consortium, a new Innovative Health Initiative (IHI)-supported collaboration focused on accelerating solutions against drug-resistant bacterial infections through cross-sector innovation. Most recently,…
The 10th AMR Conference in Basel once again brought together some of the most passionate minds in antimicrobial research, policy, and innovation. This year’s edition was particularly energizing, not only because of the scientific progress shared, but also because of the growing sense of momentum across the entire AMR community. A powerful start: tackling [...] The post Big ideas, bold solutions:…
February 26, 2026— INCATE (INCubator for Antibacterial Therapies in Europe), the antimicrobial incubator supporting the advancement of early-stage anti-infective innovation, today announced a collaboration with the Cystic Fibrosis Foundation to advance research, innovation, and solutions addressing antimicrobial resistance (AMR). People living with cystic fibrosis (CF) are particularly vulnerable…
The INCATE Selection Committee has selected five promising ventures to receive Stage I support. Want to find out who they are? Explore the latest additions and learn more about the innovative ideas moving forward in the INCATE program. Inicure AB - I-CURE: Small molecule FPR1 agonists treat and cure resistant bacterial infections by boosting the [...] The post Introducing new Stage I ventures…
February 3, 2026 — INCATE (INCubator for Antibacterial Therapies in Europe), the antimicrobial incubator supporting the advancement of early stage anti-infectives, today announced a defining milestone in its institutional journey with the appointment of Holger Zimmermann as its first Chief Executive Officer. Holger Zimmermann brings extensive experience in industrial research, biotechnology…
Every year, selecting the finalists for the Startup Pitch Event becomes more challenging, and 2026 was no exception. The level of creativity, ambition, and innovation we saw this year was truly impressive. A huge thank-you to everyone who submitted a pitch: you made the decision incredibly tough! We’re excited to welcome the finalists to the [...] The post The Finalists for the Startup Pitch Event…
January 21, 2026 – The Japan Pharmaceutical Manufacturers Association (JPMA) has joined forces with INCATE (INCubator for Antimicrobial Therapies in Europe), strengthening global collaboration to support innovation and solutions against antimicrobial resistance (AMR). INCATE brings together academic research, industry, investors, and public sector organizations to support early-stage innovators…
January 13, 2026 — INCATE (INCubator for Antibacterial Therapies in Europe), the antimicrobial incubator supporting the advancement of early stage anti-infectives, announced today a partnership with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections. Basilea is joining…
Just before turning the page to 2026, it’s worth pausing to reflect on both the progress made and the challenges that remain in the fight against antimicrobial resistance (AMR). The numbers, unfortunately, haven’t changed. According to The Lancet, up to 39 million lives could be lost to antibiotic-resistant infections by 2050 if we fail to [...] The post 2025: the year in review — progress, proof,…